News & Events

Andarix Pharmaceuticals Receives Pancreatic Cancer Orphan Drug Designation from the FDA

Jul 6, 2014

Targeted therapy for pancreatic cancer is based on personalized medicine approach ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung cancer announced today that Tozaride, the Company’s lead candidate for targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the…

Read More

Andarix Receives Orphan Drug Designation from the FDA for Small Cell Lung Cancer

Feb 16, 2014

Novel Targeted and Personalized Medicine Approach to Lung Cancer ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and neuroendocrine cancers announced today that Tozaride, the Company’s targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of small…

Read More